Wednesday, September 13, 2023 Daily Archives

MHRA greenlights Rentschler CGT plant

by

Following an MHRA approval, Rentschler Biopharma’s site in Stevenage, UK is set for clinical production of AAV vectors for gene therapies. The family-owned contract development manufacturing organization (CDMO) Rentschler Biopharma announced its plans in February 2021 to set up production capabilities at the UK’s Cell and Gene Therapy (CGT) Catapult in Stevenage, launching itself into the regenerative medicine space. After a successful inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA), the site has received the cGMP Manufacturing…

2seventy banks big on Abecma as it cuts 40% of workforce

by

2seventy says it is refocusing its efforts on CAR-T therapy Abecma as a restructure sees it cut 176 jobs – 40% of its workforce – to help free up $130+ million. Having spun-out of Bluebird bio in 2021, 2seventy took responsibility for codeveloping Abecma (ide-cel) with Bristol Myers Squibb and saw success months later when the anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell therapy won US approval for multiple myeloma 2seventy’s decision to reduce headcount this week follows…

Moderna, Immatics ink $120m cancer-focused partnership

by

The multi-platform cancer-focused partnership will see Moderna combine its mRNA technology with Immatics’ TCR platform. In its latest deal to expand beyond COVID-19, messenger RNA (mRNA) firm Moderna has partnered with German drug developer Immatics to develop cancer vaccines and therapeutics. Moderna will pay the company $120 million upfront in cash. If specific development, regulatory, and commercial milestones are met, Immatics could receive over $1.7 billion in payments. According to both parties, the R&D collaboration will focus on three elements.…